Princess Máxima Center for Pediatric Oncology.
Department of Radiation Oncology, University Medical Center Utrecht, Utrecht.
J Pediatr Hematol Oncol. 2022 May 1;44(4):117-134. doi: 10.1097/MPH.0000000000002445. Epub 2022 Apr 6.
Radiotherapy has evolved from 2-dimensional conventional radiotherapy (2D-RT) to 3-dimensional planned radiotherapy (3D-RT). Because 3D-RT improves conformity, an altered late health outcomes risk profile is anticipated. Here, we systematically reviewed the current literature on late toxicity after 3D-RT in children treated for cancer. PubMed was searched for studies describing late toxicity after 3D-RT for childhood cancer (below 21 y). Late toxicity was defined as somatic health outcomes occurring ≥90 days after treatment. We identified 13 eligible studies, describing most frequently head/neck area tumors. Included studies reported on crude frequencies of late toxicities including subsequent tumors and conditions of organ systems. Three studies offered a global assessment of the full spectrum of late toxicity; one study compared toxicities after 2D-RT and 3D-RT. Incidence rates were typically not provided. Heterogeneity in study characteristics, small study sizes and short follow-up times precluded multivariable modeling and pooling of data. In conclusion, among the first pediatric cohorts treated with 3D-RT, a broad variety of late toxicity is reported; precise estimates of incidence, and contributions of risk factors are unclear. Continued systematic evaluation of well-defined health outcomes in survivors treated with 3D-RT, including proton therapy, is needed to optimize evidence-based care for children with cancer and survivors.
放疗已经从二维常规放疗(2D-RT)发展到三维适形放疗(3D-RT)。由于 3D-RT 提高了适形性,预计会改变晚期健康结果的风险状况。在这里,我们系统地回顾了关于儿童癌症接受 3D-RT 后晚期毒性的现有文献。在 PubMed 上搜索了描述儿童癌症 3D-RT 后晚期毒性的研究(年龄小于 21 岁)。晚期毒性定义为治疗后≥90 天发生的躯体健康结果。我们确定了 13 项符合条件的研究,这些研究描述了头颈部区域肿瘤的最常见情况。纳入的研究报告了晚期毒性的粗频率,包括随后的肿瘤和器官系统的情况。三项研究对晚期毒性的全貌进行了全球评估;一项研究比较了 2D-RT 和 3D-RT 的毒性。发病率通常没有提供。研究特征、研究规模小和随访时间短的异质性使得无法进行多变量建模和数据汇总。总之,在第一批接受 3D-RT 治疗的儿科队列中,报告了多种晚期毒性;发病率的准确估计和危险因素的贡献尚不清楚。需要对接受 3D-RT(包括质子治疗)治疗的幸存者进行明确健康结果的系统评估,以优化基于证据的癌症儿童和幸存者的护理。